An International Pulmonary Embolism Registry Using EKOS

NCT ID: NCT03426124

Last Updated: 2023-02-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1480 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-03-01

Study Completion Date

2020-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This registry is designed to understand acoustic pulse thrombolysis (APT) treatment regimens used as standard of care globally for pulmonary embolism. The registry will include individuals who have already received the APT treatment and those that will undergo APT treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

For the prospective arm of the registry, a physician will have selected the APT procedure for the treatment of pulmonary embolism. The APT treatment and follow-up assessments are per clinical judgement and institutional standard of care which may vary at each clinical site.

For the retrospective arm of the registry, the investigators will gather data from consecutive cases of individuals who received the APT treatment for pulmonary embolism. Specific baseline, treatment, and long-term health information is collected and de-identified.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Embolism and Thrombosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Retrospective

Individuals with intermediate-high or high risk pulmonary embolism who were consecutively treated with the Ekosonic Endovascular System (EKOS) and thrombolytic drug between January 2014 and one year prior to site activation.

EkoSonic Endovascular System with thrombolytic

Intervention Type DEVICE

The device uses ultrasonic waves in combination with clot-dissolving thrombolytic drug to effectively dissolve clots.

Prospective

Individuals who are experiencing intermediate-high or high risk pulmonary embolism where the treating investigator has selected the EKOS device and thrombolytic drug. The duration of ultrasound and volume of thrombolytic drug are selected per physician discretion.

EkoSonic Endovascular System with thrombolytic

Intervention Type DEVICE

The device uses ultrasonic waves in combination with clot-dissolving thrombolytic drug to effectively dissolve clots.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EkoSonic Endovascular System with thrombolytic

The device uses ultrasonic waves in combination with clot-dissolving thrombolytic drug to effectively dissolve clots.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Acoustic Pulse Thrombolysis EKOS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Treated with APT procedure between January 1, 2014 and one year prior to site activation
* RV/LV ≥ 1.0 from diagnostic computed tomographic angiography (CTA) or echocardiogram
* PE symptom duration ≤ 14 days
* Troponin elevation


* Male or female ≥ 18 years of age and ≤ 80 years of age
* RV/LV ≥ 1.0 from diagnostic computed tomographic angiography (CTA) or echocardiogram
* PE symptom duration ≤ 14 days
* Troponin elevation
* Signed informed consent obtained from participant or legally authorized representative
* Investigator has selected the EKOS device to treat participant with massive or submassive pulmonary embolism

Exclusion Criteria

* Enrollment into the OPTALYSE PE study


* High-risk for catastrophic bleeding
* Life expectancy \< one year
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BTG International Inc.

OTHER

Sponsor Role collaborator

Boston Scientific Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Keith Sterling, MD

Role: PRINCIPAL_INVESTIGATOR

Inova Alexandria Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Healthfinity, PLLC Advanced Cardiac & Vascular Clinic

Glendale, Arizona, United States

Site Status

Cedars - Sinai

Los Angeles, California, United States

Site Status

Radiology Imaging Associates

Englewood, Colorado, United States

Site Status

Bradenton Cardiology Center

Bradenton, Florida, United States

Site Status

Delray Medical Center

Delray Beach, Florida, United States

Site Status

St. Vincent's Healthcare

Jacksonville, Florida, United States

Site Status

University of Florida

Jacksonville, Florida, United States

Site Status

Memorial Hospital

Jacksonville, Florida, United States

Site Status

University of Miami

Miami, Florida, United States

Site Status

Florida Hospital

Orlando, Florida, United States

Site Status

Orlando Health, Inc.

Orlando, Florida, United States

Site Status

Tallahassee Research Institute, Inc

Tallahassee, Florida, United States

Site Status

AdventHealth Tampa Pepin Heart Institute

Tampa, Florida, United States

Site Status

Emory University

Atlanta, Georgia, United States

Site Status

Augusta University

Augusta, Georgia, United States

Site Status

WellStar Medical Group

Marietta, Georgia, United States

Site Status

Northwestern University

Chicago, Illinois, United States

Site Status

Loyola University Medical Center

Maywood, Illinois, United States

Site Status

St. Mary Medical Center

Hobart, Indiana, United States

Site Status

St. Vincent Hospital

Indianapolis, Indiana, United States

Site Status

St. Elizabeth Healthcare

Crestview Hills, Kentucky, United States

Site Status

University of Kentucky

Lexington, Kentucky, United States

Site Status

Jewish Hospital

Louisville, Kentucky, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Brigham & Women's Hospital

Boston, Massachusetts, United States

Site Status

St. Vincent Hospital/Reliant Medical Group

Worcester, Massachusetts, United States

Site Status

University of Michigan Health System

Ann Arbor, Michigan, United States

Site Status

Ascension St. John Hospital

Detroit, Michigan, United States

Site Status

Spectrum Health

Grand Rapids, Michigan, United States

Site Status

Metro Health - University of Michigan Health

Wyoming, Michigan, United States

Site Status

Cardiology Associates of Northern Mississippi

Oxford, Mississippi, United States

Site Status

Saint Louis University Hospital

St Louis, Missouri, United States

Site Status

Dartmouth - Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

Cooper University Healthcare

Camden, New Jersey, United States

Site Status

University of Buffalo

Buffalo, New York, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

East Carolina University

Greenville, North Carolina, United States

Site Status

Wake Forest Baptist Health

Winston-Salem, North Carolina, United States

Site Status

Summa Health

Akron, Ohio, United States

Site Status

Mercy Health Cincinnati

Cincinnati, Ohio, United States

Site Status

University of Cincinnati

Cincinnati, Ohio, United States

Site Status

TriHealth Good Samaritan Bethesda North

Cincinnati, Ohio, United States

Site Status

Ohio State University

Columbus, Ohio, United States

Site Status

Mount Caramel East Hospital

Columbus, Ohio, United States

Site Status

University of Toledo

Toledo, Ohio, United States

Site Status

Genesis Healthcare System

Zanesville, Ohio, United States

Site Status

Oregon Health & Science University

Portland, Oregon, United States

Site Status

St. Luke's University Health Network

Bethlehem, Pennsylvania, United States

Site Status

St. Vincent Hospital, Allegheny Health Network

Erie, Pennsylvania, United States

Site Status

Temple University Hospital, Department of Thoracic Medicine & Surgery

Philadelphia, Pennsylvania, United States

Site Status

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

Site Status

UPMC Hamot

Pittsburgh, Pennsylvania, United States

Site Status

Lankenau Medical Center

Wynnewood, Pennsylvania, United States

Site Status

Lexington Cardiology

West Columbia, South Carolina, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

Hendrick Medical Center

Abilene, Texas, United States

Site Status

The Heart Hospital Baylor Plano

Plano, Texas, United States

Site Status

Houston Methodist Sugarland

Sugar Land, Texas, United States

Site Status

Inova Alexandria Hospital

Alexandria, Virginia, United States

Site Status

Sentara Vascular Specialists

Norfolk, Virginia, United States

Site Status

Providence Regional Medical Center

Everett, Washington, United States

Site Status

Inland Imaging

Spokane, Washington, United States

Site Status

CAMC

Charleston, West Virginia, United States

Site Status

West Virginia University Heart & Vascular Institute

Morgantown, West Virginia, United States

Site Status

Aurora Cardiovascular Services

Milwaukee, Wisconsin, United States

Site Status

Medical University of Vienna

Vienna, , Austria

Site Status

CHRU jean Minjoz, Pôle cœur-Poumons

Besançon, , France

Site Status

Hôpital Nord, APHM

Marseille, , France

Site Status

Johannes Gutenberg Univeristy Mainz

Mainz, , Germany

Site Status

Technical University Munchen

München, , Germany

Site Status

University Medical Center Uterecht

Utrecht, , Netherlands

Site Status

Swiss Cardiovascular Center

Bern, , Switzerland

Site Status

University Hospital Zurich

Zurich, , Switzerland

Site Status

Acibadem University School of Medicine

Istanbul, , Turkey (Türkiye)

Site Status

Royal Devon and Exeter Hospital

Exeter, , United Kingdom

Site Status

Medway NHS Foundation Trust

Gillingham, , United Kingdom

Site Status

Oxford University Hospitals

Headington, , United Kingdom

Site Status

Royal Free

London, , United Kingdom

Site Status

Guy's & St Thomas' NHS Foundation Trust

London, , United Kingdom

Site Status

St. Mary's Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria France Germany Netherlands Switzerland Turkey (Türkiye) United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Sterling KM, Goldhaber SZ, Sharp ASP, Kucher N, Jones N, Maholic R, Meneveau N, Zlotnick D, Sayfo S, Konstantinides SV, Piazza G. Prospective Multicenter International Registry of Ultrasound-Facilitated Catheter-Directed Thrombolysis in Intermediate-High and High-Risk Pulmonary Embolism (KNOCOUT PE). Circ Cardiovasc Interv. 2024 Mar;17(3):e013448. doi: 10.1161/CIRCINTERVENTIONS.123.013448. Epub 2024 Jan 24.

Reference Type DERIVED
PMID: 38264938 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BTG-001653-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Mechanical Thrombectomy for Acute Pulmonary Embolism
NCT07032025 NOT_YET_RECRUITING EARLY_PHASE1